Article
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.
Molecular cancer therapeutics - 1 Aug 2015
LoRusso Patricia M, Boerner Scott A, Pilat Mary Jo, Forman Karen M, Zuccaro Clarice Y, Kiefer Jeffrey A, Liang Winnie S, Hunsberger Sally, Redman Bruce G, Markovic Svetomir N, Sekulic Aleksandar, Bryce Alan H, Joseph Richard W, Cowey C Lance, Fecher Leslie Anne, Sosman Jeffrey Alan, Chapman Paul B, Schwartz Gary K, Craig David W, Carpten John D, Trent Jeffrey M
Abstract excerpt
Targeted therapies and immunotherapies have led to significant improvements in the treatment of advanced cancers, including metastatic melanoma. However, new strategies are desperately needed to overcome therapeutic resistance to these agents, as well as to identify effective treatment approaches for cancer patients that fall outside major targetable mutational subtypes (e.g., non-V600 BRAF melanoma). One such...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.